NICE turns down Novartis’ Adakveo
Trial results and cost-effectiveness are too uncertain for NHS use, the Institute said
Read More
Tag: Crizanlizumab
Eleven medicines backed for EU approval
Recommendations include the first antibody-drug conjugate for multiple myeloma patients with limited treatment options
Read More
Novartis’ crizanlizumab granted FDA Breakthrough Therapy
US regulators have granted Novartis’ crizanlizumab (SEG101) Breakthrough Therapy designation for the prevention of vaso-occlusive crises in patients with sickle cell disease.
Read More
Novartis crizanlizumab shows promise in sickle cell anaemia
A new analysis has shown that Novartis’ crizanlizumab reduced the number of patients with sickle cell disease experiencing a pain crisis.
Read More
- MHRA to open new Northern Ireland hub to strengthen UK‑wide life sciences collaboration
- Novo Nordisk data shows oral semaglutide delivers significant weight loss in phase 3 trial
- Enterprise reports positive phase 2 data for inhaled ENaC blocker in cystic fibrosis
- SMC backs first-line metastatic bladder cancer combination after trial results
- Poolbeg secures Canadian patent for POLB 001 in cancer immunotherapy‑induced CRS
